Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Go back to Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.67 -1.34 (2.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.01 | 52 Week High | $17.00 | |||
| Open | $58.97 | 52 Week Low | $3.55 | |||
| Day High | $59.41 | P/E | N/A | |||
| Day Low | $57.55 | EPS | $-1.33 | |||
| Volume | 2,538,923 | |||||
